The Developmental and Translational Study on Biomarkers and Clinical Characteristics-based Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China

• Published in: Neuropsychiatric disease and treatment 2020-01, Vol.16, p.2343-2351
• Main Authors: Liu, Xiaohua, Wang, Yun, Peng, Daihui, Zhang, Huifeng, Zheng, Yanqun, Wu, Yan, Su, Yun-Ai, Liu, Ming, Ma, Xiancang, Li, Yi, Shi, Jianfei, Cheng, Xiaojing, Rong, Han, Fang, Yiru
• Format: Article
• Language: English
• Subjects: antidepressant; Antidepressants; Anxiety; Biological markers; Biomarkers; Care and treatment; computerized cognitive behavioral treatment (ccbt); Diagnosis; EEG; Intervention; Magnetic resonance imaging; Major depressive disorder; major depressive disorder (mdd); Medical diagnosis; Medical treatment; Melatonin; Mental depression; Mental disorders; Patients; physical therapy; Psychotherapy; Psychotropic drugs; randomized controlled trial (rct); Study Protocol; subtype; Translational research
• ISSN: 1176-6328; 1178-2021; 1178-2021
• DOI: 10.2147/NDT.S271842

Major depressive disorder (MDD) is a heterogeneous mental disease that encompasses different subtypes and specifiers. Clinically targeted treatments have not been identified yet, although standardized strategies are recommended by several clinical guidelines. The main aim of this study is to respectively identify the precise treatment for three different subtypes of MDD (ie, melancholic, atypical, and anxious). An 8-to-12-week, multicenter randomized controlled trial (RCT) with a parallel group design will be conducted to determine the most effective and appropriate treatment. A total of 750 adults diagnosed with MDD will be recruited, categorized into melancholic, atypical or anxious type based on the assessment of the Inventory of Depressive Symptomatology (IDS30) and the Hamilton Anxiety Scale (HAMA), and 1:1 randomly assigned to different intervention groups. Blood draw, EEG test, and MRI scan will be performed at baseline and endpoint. Clinical symptom and side-effects will be evaluated at critical decision points (CDP) including weeks two, four, six, eight, and 12 after treatment. The primary outcome is total score and reduction rate of the 17-Hamilton Depression Rating Scale (17-HDRS). The secondary outcomes include the scores of the Quick Inventory of Depressive Symptomatology-self-report (QIDS-SR), IDS30, HAMA and the Treatment Emergent Symptom Scale (TESS). All the data will be analyzed by SAS software. The study commenced recruitment in August 2017 and is currently ongoing. ClinicalTrials.gov Identifier: NCT03219008 (July 17, 2017).